<DOC>
	<DOCNO>NCT00938886</DOCNO>
	<brief_summary>To test whether naltrexone compare placebo reduce heavy drinking improve smoking cessation outcomes heavy drinker seek smoke cessation treatment .</brief_summary>
	<brief_title>Naltrexone At-Risk Problem Drinking Smoking Cessation Treatment</brief_title>
	<detailed_description>A substantial portion individual seek behavioral pharmacological treatment smoke cessation drink excessively many report significant alcohol problem . Although at-risk problem drinker unlikely choose abstinence alcohol goal , many make substantial reduction drink quit smoking attempt . Thus , context smoking cessation treatment offer unique valuable opportunity apply brief intervention pharmacotherapy catalyze change excessive drinking population markedly elevate risk negative health outcome . In recent randomized clinical trial , standard smoke cessation treatment incorporate brief alcohol intervention show promise reduce drink well improve smoke cessation outcome among heavy drinker . However , effect relatively modest , especially among heavy drinker , indicate study warrant method address heavy drinking smoke cessation include use relevant pharmacotherapy . Naltrexone , particular , show promise purpose . The overall aim project test efficacy naltrexone pharmacotherapy excessive drinking deliver at-risk problem drinker seek smoke cessation treatment . The proposed clinical trial use between-subjects design 300 at-risk problem drinker seek treatment smoke cessation randomly assign receive either daily 50 mg naltrexone placebo . Medication initiate 2 week prior participant ' smoke quit date continue 10 week . All participant also receive transdermal nicotine patch counsel medication management intervention provide advice smoke cessation , advice regard effect heavy drink smoke cessation health , monitor encouragement compliance medication . Drinking smoke outcome assess 2 , 8 , 16 , 26 week participant ' smoke quit date . The primary aim study test hypothesis naltrexone result great reduction heavy drink relative placebo . The secondary aim test whether naltrexone result superior smoke outcomes relative placebo , tertiary aim examine interrelationship among motivation change drinking , compliance naltrexone , drink smoke outcomes . This study represent first kind provide naltrexone conjunction opportunistic brief alcohol intervention at-risk problem drinker seek alcohol treatment . Testing potential benefit naltrexone among at-risk problem drinker smoke high significance public health effort reduce markedly elevate rate morbidity mortality observe large , yet relatively understudied group .</detailed_description>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . ) least 18 year age , 2 . ) drink heavily least per month average ( ≥4 drink per occasion woman ; ≥5 drink men ) , 3 . ) smoke cigarette regularly least one year , 4 . ) currently smoke least 5 cigarette day , 5 . ) currently use tobacco product nicotine replacement therapy 1 . ) meet criterion current substance dependence ( exclude nicotine alcohol ) ; 2 . ) report opiate use past month , drug screen positive opiate , require opiate containing medication pain management ; 3 . ) meet criterion current major depressive manic episode ; 4 . ) currently psychotic suicidal ; 5 . ) unstable serious medical condition would preclude use nicotine patch naltrexone ( e.g. , unstable angina pectoris , severe arrhythmia , recent congestive heart failure ) ; 6 . ) aspartate aminotransferase alanine aminotransferase level 3 time reference range elevate bilirubin level ; 7 . ) currently pregnant lactating , intend become pregnant , use reliable mean birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>